Merck, Amgen Double Down on Bad Cholesterol to Vanquish Number 1 Killer

Why It Matters

The stricter LDL‑C targets create a sizable commercial gap that oral PCSK9 and Lp(a) drugs can fill, potentially reshaping cardiovascular‑risk management and generating billions in revenue.

Key Takeaways

• Enlicitide cut LDL‑C 64.6% in eight‑week Phase III trial.
• New ACC/AHA guidelines set LDL‑C <55 mg/dL for ASCVD patients.
• ~70% of statin users fail to meet updated LDL targets.
• Oral PCSK9 inhibitor offers convenience over injectable Repatha.
• Companies pour billions into Lp(a) therapies targeting 50 million high‑risk Americans.

Pulse Analysis

Heart disease remains the United States' leading cause of death, and the March 2026 ACC/AHA lipid guideline revision tightens LDL‑C goals to <100 mg/dL for intermediate risk, <70 mg/dL for high risk, and <55 mg/dL for patients with established ASCVD. The stricter thresholds expose a sizable treatment gap—about 70 % of statin‑treated adults still exceed the targets—creating a multi‑billion‑dollar opportunity for next‑generation lipid‑lowering agents. Investors and payers are now scrutinizing therapies that can deliver deeper LDL reductions with better adherence.

Merck's oral PCSK9 inhibitor enlicitide delivered a 64.6 % LDL‑C reduction after eight weeks in its Phase III CORALreef AddOn study, outperforming existing oral non‑statin options and matching the efficacy of injectable monoclonal antibodies. The daily pill format addresses the injection fatigue that has limited Repatha’s market penetration, despite Amgen’s $3 billion 2025 sales. Guggenheim Partners projects enlicitide could surpass the current $2.8 billion 2033 revenue consensus, buoyed by a reported 97 % adherence rate in early trials.

Beyond LDL‑C, the new guidelines spotlight lipoprotein(a) as a complementary risk factor, prompting a wave of R&D investment. Merck has allocated roughly $2 billion to a joint venture with Jiangsu Hengrui on the Lp(a)‑lowering molecule HRS‑5346, while AstraZeneca, Eli Lilly and Amgen are advancing their own candidates. With an estimated 50 million Americans exhibiting elevated Lp(a), a successful therapy could unlock a sizable unmet market and further diversify revenue streams for the cholesterol‑focused big pharma players.